Page last updated on July 16, 2024
BURZYNSKI RESEARCH INSTITUTE INC reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-05-29 16:15:43 EDT.
Filings
10-K filed on 2024-05-29
BURZYNSKI RESEARCH INSTITUTE INC filed a 10-K at 2024-05-29 16:15:43 EDT
Accession Number: 0001558370-24-008731
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
ITEM 1C. CYBE RSECURITY Risk Management and Strategy We have certain processes for the identification, assessment, and mitigation of cybersecurity risks which are incorporated into our overall risk management processes, which we rely on information technology systems and networks managed and maintained by independent third parties. Our information technology personnel, responsible for cyber security, monitors daily and weekly backups of our system to protect against data loss and minimize disruption to our operations in the event of a cybersecurity incident. Our data is accessible by our assigned personnel and third parties as necessary and appropriate, to perform services or otherwise do business with us, and we have implemented two-factor identification for access to our third party systems to submit relevant data to our IND. We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. Governance Our information technology personnel and our senior management lead the operational oversight of the company-wide cybersecurity strategy and processes. The board of directors provides oversight of our cybersecurity risk. Additionally, the board of directors reviews our enterprise risk management processes and will be notified by management between management updates regarding significant new cybersecurity threats or incidents.
Company Information
Name | BURZYNSKI RESEARCH INSTITUTE INC |
CIK | 0000724445 |
SIC Description | In Vitro & In Vivo Diagnostic Substances |
Ticker | BZYR - OTC |
Website | |
Category | Non-accelerated filer Smaller reporting company |
Fiscal Year End | February 28 |